LEGAL FAQs

In April of 2020, the FDA announced that all Zantac brand, both prescription and over-the-counter versions, should be immediately pulled from the market.

On September 13, 2019, the U.S. Food and Drug Administration (FDA) reported the discovery of the carcinogenic contaminant N-nitrosodimethylamine (NDMA) in Zantac. NDMA was found in Zantac at levels beyond what is considered safe. Scientific research has shown when ranitidine comes in contact with water, it creates a chemical reaction that causes the formation of NDMA. Studies have linked the NDMA to cancer in animals and humans.

A carcinogenic contaminant N-nitrosodimethylamine (NDMA) is a carcinogenic contaminant that has been linked to cancer in patients that have taken the drug. NDMA is a volatile, combustible, yellow, oily liquid nitrosamine with a faint characteristic odor. The chemical decomposes when exposed to light and emits toxic fumes when heated. NDMA is used primarily in research labs induce tumors in experimental animals. In 2014, the EPA issued a statement about NDMA contamination in drinking water.

In the current litigation, the plaintiffs allege that the manufacturers placed on the market a dangerous product and failed to warn consumers of the serious risks and side effects. The main manufacturers of Zantac include: Sanofi, Boehringer Ingelheim, and GSK.

• Bladder
• Colon
• Pancreatic
• Esophageal
• Kidney
• Liver
• Stomach/Gastric
• Breast
• Lung
• Prostate

Any person or family member of a person who has a history of taking Zantac and received a cancer diagnosis may be eligible to make a claim, simply fill out the Zantac Cancer Lawsuit Form.

Our attorneys are committed to representing all persons involved in a Zantac lawsuit on a contingency basis, meaning there are never any legal fees unless we win compensation in your case.

CLICK HERE to Contact Wolf Edlund, P.C. Immediately